Skip to Main Content

Paper Details

Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10.
Cancers (Basel)
15
2020
5-FU, 5-fluorouracil, CF10, E2F1-3, Fluoropyrimidine, PDOs, Patient, Polymeric, Pyrimidine, RNA, SCLC, SCLC Patient, SCLC Patient-Derived Organoids, TS, TYMS, Thymidylate synthase, anti, cisplatin, fluoropyrimidine, human, patient, platinum, pyrimidine, small cell lung cancer, tumor
Author NameAffiliation
Lance D MillerWake Forest School of Medicine
Lance D MillerComprehensive Cancer Center Wake Forest School of Medicine
Jeff W ChouComprehensive Cancer Center Wake Forest School of Medicine
Frank C MariniWake Forest School of Medicine
Frank C MariniComprehensive Cancer Center Wake Forest School of Medicine
Frank C MariniWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine
Frank C MariniWake Forest School of Medicine
Frank C MariniComprehensive Cancer Center Wake Forest School of Medicine
Frank C MariniWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine
  • 1 - 9

Datasets

Release 1.2